Effect of nanoparticles on transdermal drug delivery.

Institut für Pharmazeutische Technologie, J. W. Goethe-Universität, Frankfurt, Germany.
Journal of Microencapsulation (Impact Factor: 1.88). 01/1991; 8(3):369-74. DOI: 10.3109/02652049109069563
Source: PubMed

ABSTRACT The purpose of the present study was to assess by in vitro means the effect of poly (methylmethacrylate) nanoparticles and poly (butylcyanoacrylate) nanoparticles on transdermal drug delivery. Methanol and octanol were chosen as test permeants. In order to distinguish between thermodynamic effect and those due to biological consequences, two different membranes were employed, i.e., full thickness hairless mouse skin and silicone elastomer sheeting (175 microns). It is evident that poly (methylmethacrylate) nanoparticles and poly (butylcyanoacrylate) nanoparticles increase the permeability of methanol through hairless mouse skin by a factor of 1.2-2. The permeability of lipophilic octanol is either unaffected by nanoparticles or decreases as a function of nanoparticle concentration depending on the lipophilicity of the polymer material.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In vitro permeation of nabumetone across rat skin from nanoemulsions of soybean oil in 2.5% aqueous glycerol stabilized with a blend of lecithin and 1‐O‐alkylglycerol (C10, C12, C14, or C16 chain length) was studied. The mean droplet size of the emulsions was in the range of 214 to 280 nm. 1‐O‐Alkylglycerol stabilized emulsions showed significant enhancement in permeation of nabumetone. This enhancement is attributed to the interaction of 1‐O‐alkylglycerol with the skin lipids, fluidizing the lipid matrix and bringing about disordering effect. The extent of interaction appears to depend on chain length of 1‐O‐alkylglycerol. 1‐O‐Decylglycerol stabilized emulsion showed highest flux in the first four hours and did not exhibit any lag time. The other emulsions showed increase in lag time with increase in the chain length of 1‐O‐alkylglycerol. Control nabumetone solution exhibited highest overall flux, but it showed lower flux than nanoemulsions stabilized by 1‐O‐decylglycerol for the initial four hours and a significantly higher flux thereafter. This appears to be due to slow extraction of skin lipid by the solvent action of control solution and consequent permeabilization of the skin.
    Journal of Dispersion Science and Technology - J DISPER SCI TECH. 01/2006; 27(7):921-926.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The delivery of therapeutic agents is characterised by numerous challenges including poor absorption, low penetration in target tissues and unspecific dissemination in organs, leading to toxicity or poor drug exposure. Several nanomedicine strategies have emerged as an advanced approach to enhance drug delivery and improve the treatment of several diseases. Numerous processes mediate the pharmacokinetics of nanoformulations, with the absorption, distribution, metabolism and elimination (ADME) being poorly understood and often differing substantially from traditional formulations. Understanding how nanoformulation composition and physicochemical properties influence drug distribution in the human body is of central importance when developing future treatment strategies. A helpful pharmacological tool to simulate the distribution of nanoformulations is represented by physiologically based pharmacokinetics (PBPK) modelling, which integrates system data describing a population of interest with drug/nanoparticle in vitro data through a mathematical description of ADME. The application of PBPK models for nanomedicine is in its infancy and characterised by several challenges. The integration of property-distribution relationships in PBPK models may benefit nanomedicine research, giving opportunities for innovative development of nanotechnologies. PBPK modelling has the potential to improve our understanding of the mechanisms underpinning nanoformulation disposition and allow for more rapid and accurate determination of their kinetics. This review provides an overview of the current knowledge of nanomedicine distribution and the use of PBPK modelling in the characterisation of nanoformulations with optimal pharmacokinetics.
    British Journal of Pharmacology 01/2014; · 5.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transdermal drug delivery offers an attractive alternative to the conventional drug-delivery methods of oral administration and injection. Apart from the convenience and noninvasiveness, the skin also provides a “reservoir” that sustains delivery over a period of days. It offers multiple sites to avoid local irritation and toxicity, yet it can also offer the option of concentrating drugs at local areas to avoid undesirable systemic effects. However, at present, the clinical use of transdermal delivery is limited by the fact that very few drugs can be delivered transdermally at a viable rate. This difficulty is because the stratum corneum of skin acts as an efficient barrier that limits penetration of drugs through the skin, and few noninvasive methods are known to significantly enhance the penetration of this barrier. In order to increase the range of drugs available for transdermal delivery, the use of nanocarriers has emerged as an interesting and valuable alternative for delivering lipophilic and hydrophilic drugs throughout the stratum corneum with the possibility of having a local or systemic effect for the treatment of many different diseases. These nanocarriers (nanoparticles, ethosomes, dendrimers, liposomes, etc) can be made of a lot of different materials, and they are very different in structure and chemical nature. They are too small to be detected by the immune system, and furthermore they can deliver the drug in the target organ using lower drug doses in order to reduce side effects.
    Research and Reports in Transdermal Drug Delivery. 11/2012; 2012:1(1):3.